SG47857A1 - N-acyl derivatites of the ll-e33288 antitumor antibiotics - Google Patents

N-acyl derivatites of the ll-e33288 antitumor antibiotics

Info

Publication number
SG47857A1
SG47857A1 SG1996004747A SG1996004747A SG47857A1 SG 47857 A1 SG47857 A1 SG 47857A1 SG 1996004747 A SG1996004747 A SG 1996004747A SG 1996004747 A SG1996004747 A SG 1996004747A SG 47857 A1 SG47857 A1 SG 47857A1
Authority
SG
Singapore
Prior art keywords
acyl
derivatites
antitumor antibiotics
antitumor
antibiotics
Prior art date
Application number
SG1996004747A
Other languages
English (en)
Inventor
May Dean-Ming Lee
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of SG47857A1 publication Critical patent/SG47857A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/29—Micromonospora

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG1996004747A 1989-04-14 1990-04-06 N-acyl derivatites of the ll-e33288 antitumor antibiotics SG47857A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/338,928 US5079233A (en) 1987-01-30 1989-04-14 N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same

Publications (1)

Publication Number Publication Date
SG47857A1 true SG47857A1 (en) 1998-04-17

Family

ID=23326735

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004747A SG47857A1 (en) 1989-04-14 1990-04-06 N-acyl derivatites of the ll-e33288 antitumor antibiotics

Country Status (23)

Country Link
US (1) US5079233A (de)
EP (2) EP0392376B1 (de)
JP (1) JP3083309B2 (de)
KR (1) KR0149493B1 (de)
CN (1) CN1027267C (de)
AT (2) ATE297405T1 (de)
AU (1) AU627863B2 (de)
CA (1) CA2014472C (de)
CZ (2) CZ297668B6 (de)
DE (2) DE69034194T2 (de)
DK (2) DK1097937T3 (de)
ES (2) ES2162783T3 (de)
FI (1) FI97889C (de)
HK (2) HK1035540A1 (de)
IE (1) IE20011013A1 (de)
IL (1) IL93732A (de)
NO (1) NO172938C (de)
NZ (1) NZ233149A (de)
PH (1) PH27361A (de)
PT (1) PT93715B (de)
SG (1) SG47857A1 (de)
SK (1) SK281179B6 (de)
ZA (1) ZA902839B (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1997014421A1 (en) * 1995-10-20 1997-04-24 University Of Utah Research Foundation Namenamicin, an enediyne antitumor antibiotic from the marine ascidian polysyncraton lithostrotum
EP2261335B1 (de) 1998-11-27 2017-06-14 UCB Pharma S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7608681B2 (en) * 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
KR101062628B1 (ko) 2002-05-02 2011-09-07 와이어쓰 홀딩스 코포레이션 칼리치아미신 유도체-운반체 접합체
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
US20050282168A1 (en) * 2003-09-29 2005-12-22 Wyeth Cell surface molecules as markers and therapeutic agents against kidney cancers
EP2478912B1 (de) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung
ATE554107T1 (de) 2003-12-19 2012-05-15 Genentech Inc Als therapeutika geeignete monovalente antikörperfragmente
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20060222850A1 (en) * 2005-04-01 2006-10-05 The University Of Chicago Synthesis of a self assembled hybrid of ultrananocrystalline diamond and carbon nanotubes
HUE028441T2 (hu) * 2004-09-03 2016-12-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
EP1786469A2 (de) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Humanisierte anti-5t4-antikörper und anti-5t4-antikörper-/calicheamicinkonjugate
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
EP1796718A2 (de) * 2004-10-05 2007-06-20 Genentech, Inc. Therapeutische mitteln mit erniedriegter toxizität
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
RU2470941C2 (ru) * 2005-12-02 2012-12-27 Дженентек, Инк. Связывающие полипептиды и их применения
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2006321975A1 (en) * 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
CA2633887C (en) 2005-12-15 2015-12-22 Genentech, Inc. Methods and compositions for targeting polyubiquitin
BRPI0706840A2 (pt) 2006-01-05 2011-04-05 Genentech Inc anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
PA8718601A1 (es) 2006-03-10 2009-05-15 Wyeth Corp Anticuerpos anti-5t4 y sus usos
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
DK2845866T3 (en) 2006-10-27 2017-07-10 Genentech Inc Antibodies and immunoconjugates and their applications
CL2008000420A1 (es) 2007-02-09 2008-06-27 Genentech Inc Anticuerpo anti-robo4; y su uso para modular la angiogenesis.
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2687852A1 (en) 2007-05-22 2008-12-04 Wyeth Improved processes for making hydrazides
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
ES2758126T3 (es) 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US8597652B2 (en) 2009-03-20 2013-12-03 Genentech, Inc. Multispecific anti-HER antibodies
HRP20221471T1 (hr) 2009-03-25 2023-02-03 Genentech, Inc. Protutijela anti-fgfr3 i postupci za njihovu uporabu
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
EP2491058A1 (de) * 2009-10-19 2012-08-29 F. Hoffmann-La Roche AG Modulatoren des hepatozytenwachstumsfaktoraktivators
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
AU2010310585A1 (en) 2009-10-22 2012-05-03 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
MX2012005168A (es) 2009-11-05 2012-06-08 Genentech Inc Metodos y composicion para secrecion de polipeptidos heterologos.
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
AR079704A1 (es) 2009-12-23 2012-02-15 Genentech Inc Anticuerpos anti-bv8 y sus usos
KR101723615B1 (ko) 2010-01-12 2017-04-06 한상선 천연 한약재를 이용한 샴푸 조성물
AU2011213609B2 (en) 2010-02-08 2016-11-03 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
MX336109B (es) 2010-06-03 2016-01-08 Genentech Inc Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
PL3409287T3 (pl) 2010-09-29 2021-09-27 Agensys, Inc. Koniugaty leków i przeciwciał (adc), które wiążą białka 191p4d12
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
AR088509A1 (es) 2011-10-28 2014-06-11 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma
EP2589609A1 (de) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
CN102584915B (zh) * 2011-12-31 2014-07-23 沈阳药科大学 一种芳香酸类化合物及其用途
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
MX2015000863A (es) 2012-07-19 2016-05-05 Alethia Biotherapeutics Inc Anticuerpos anti-siglec-15.
NZ731881A (en) 2012-07-25 2022-07-29 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
PH12021551473A1 (en) 2012-08-23 2022-04-25 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
JP6445444B2 (ja) 2012-11-05 2018-12-26 ピエール、ファーブル、メディカマン 新規抗原結合タンパク質および癌の治療のためのアドレッシング産物（ａｄｄｒｅｓｓｉｎｇｐｒｏｄｕｃｔ）としてのそれらの使用
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
EP3027220A1 (de) 2013-08-01 2016-06-08 Agensys, Inc. An cd37-proteine bindende antikörper-wirkstoffkonjugate (adc)
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
CA2929525A1 (en) 2013-11-04 2015-05-07 Pfizer Inc. Anti-efna4 antibody-drug conjugates
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
MX2016009332A (es) 2014-01-29 2016-12-20 Shanghai hengrui pharmaceutical co ltd Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
EP3129767B1 (de) 2014-03-27 2021-09-01 Academia Sinica Reaktive markierungsverbindungen und ihre verwendungen
EP3134438B1 (de) 2014-04-25 2020-09-30 Pierre Fabre Medicament Igf-1r-antikörper und dessen verwendung als adressierungsmedium bei der behandlung von krebs
CA2947148C (en) 2014-04-30 2022-02-08 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
KR20240096599A (ko) 2014-05-27 2024-06-26 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
TWI717319B (zh) 2014-05-27 2021-02-01 中央研究院 得自類桿菌屬之岩藻糖苷酶及其用途
CA2950433A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
AU2016209056B2 (en) 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
EP3427055A1 (de) 2016-03-07 2019-01-16 Pierre Fabre Medicament Neues universelles verfahren zur aufnahme und analyse von adcs zur charakterisierung der wirkstoffverteilung und des wirkstoff-antikörper-verhältnisses bei biologischen proben
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
EP3442567A4 (de) 2016-04-13 2019-12-18 Orimabs Ltd. Anti-psma-antikörper und verwendung davon
CN109690315A (zh) 2016-07-08 2019-04-26 豪夫迈·罗氏有限公司 人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
EP3500594A4 (de) 2016-08-22 2020-03-11 Cho Pharma Inc. Antikörper, bindungsfragmente und verfahren zur verwendung
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
WO2019110725A1 (en) 2017-12-06 2019-06-13 Synaffix B.V. Enediyne conjugates
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
JP7558156B2 (ja) 2018-09-26 2024-09-30 ジエンス ヘンルイ メデイシンカンパニー リミテッド エキサテカン類似体のリガンド－薬物コンジュゲート、その調製方法およびその適用
US20220267452A1 (en) 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
CA3150807A1 (en) 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
CA3168654A1 (en) 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
CN115103858A (zh) 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
US20230165969A1 (en) 2020-03-25 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
KR20230156727A (ko) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
AU2022265543A1 (en) 2021-04-30 2023-10-26 Pierre Fabre Medicament New stable anti-vista antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5644076B2 (de) * 1973-07-12 1981-10-16
EP1215212A3 (de) * 1987-01-30 2003-05-21 Wyeth Holdings Corporation Dihydroderivate der Antibiotika vom Typ LL-E33288
US4837206A (en) * 1987-04-29 1989-06-06 Bristol-Myers Company Esperamicin derivatives
DE3889063T2 (de) * 1987-10-30 1994-12-01 American Cyanamid Co Dischwefel-Analoge von LL-E33288 Antitumor-Verbindungen.
IL115770A (en) * 1989-04-14 1999-03-12 American Cyanamid Co Substituted disulfides of formula q-sp-ss-w their preparation and use for inhibiting the growth of tumours and for treating bacterial infections

Also Published As

Publication number Publication date
NO901654L (no) 1990-10-15
AU5324890A (en) 1990-10-18
ES2240000T3 (es) 2005-10-16
NO901654D0 (no) 1990-04-11
CA2014472A1 (en) 1990-10-14
KR0149493B1 (ko) 1998-08-17
PH27361A (en) 1993-06-21
US5079233A (en) 1992-01-07
CZ188390A3 (cs) 1998-10-14
HK1011368A1 (en) 1999-07-09
AU627863B2 (en) 1992-09-03
FI97889B (fi) 1996-11-29
IL93732A (en) 1994-11-28
DK0392376T3 (da) 2001-12-03
FI901865A0 (fi) 1990-05-12
EP1097937A1 (de) 2001-05-09
FI97889C (fi) 1997-03-10
IL93732A0 (en) 1990-12-23
NZ233149A (en) 1996-02-27
DK1097937T3 (da) 2005-09-19
DE69034194D1 (de) 2005-07-14
SK188390A3 (en) 2000-12-11
DE69033839T2 (de) 2002-06-06
NO172938C (no) 1993-12-29
PT93715B (pt) 1996-08-30
JP3083309B2 (ja) 2000-09-04
EP0392376B1 (de) 2001-10-31
CN1027267C (zh) 1995-01-04
EP0392376A2 (de) 1990-10-17
CZ284618B6 (cs) 1999-01-13
CZ297668B6 (cs) 2007-02-28
EP1097937B1 (de) 2005-06-08
PT93715A (pt) 1990-11-20
CZ53598A3 (cs) 1998-09-16
DE69033839D1 (de) 2001-12-06
ATE297405T1 (de) 2005-06-15
EP0392376A3 (de) 1991-08-14
DE69034194T2 (de) 2005-11-03
HK1035540A1 (en) 2001-11-30
CA2014472C (en) 2000-03-28
CN1048390A (zh) 1991-01-09
NO172938B (no) 1993-06-21
ZA902839B (en) 1991-12-24
ES2162783T3 (es) 2002-01-16
JPH032192A (ja) 1991-01-08
KR900016242A (ko) 1990-11-13
SK281179B6 (sk) 2000-12-11
IE20011013A1 (en) 2002-12-30
ATE207926T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
SG47857A1 (en) N-acyl derivatites of the ll-e33288 antitumor antibiotics
ZA935893B (en) Novel 7-(substituted)-8-(substituted)-9-((substituted glycyl)amido)-6-demethyl-deoxytetracyclines
IL106673A0 (en) 7-(substituted)-9-((substituted glycyl)amido)-6-demethyl-6-deoxytetracyclines
ZA877003B (en) Glycopeptide antibiotics
HK131997A (en) Targeted forms of methyltrithio antitumor agents
CY1959A (en) Beta-lactam antibiotics
NZ221442A (en) Antibiotics from myxococcus
EP0294763A3 (en) Anthracycline antibiotics as anti-retroviral agents
IE893710L (en) Carboxyamides of teicoplanin antibiotics
IE901331L (en) N-acyl derivatives of ll-e33288 antitumor antibiotics
IL107367A0 (en) The aglycones of serine analogs of bu-3608 antibiotics
IE890337L (en) Beta-lactam antibiotics
SU1833737A1 (ru) Cпocoб лeчehия гhoйhoгo mehиhгиta
PH27270A (en) Targeted forms of methyltrithio antitumor agents
ZA902840B (en) Targeted forms of methyltrithio antitumor agents
GB8608963D0 (en) Beta-lactam antibiotics
IE872050L (en) Glycopeptide antibiotics
IE901332L (en) Targeted forms of methylthio antitumor agents
IE891862L (en) Bu-342ot antitumor antibiotic